Actually, we intended to emphasize the intensified effect of chronic viral hepatitis on insulin analogues for HCC risks, rather than the independent role of each insulin analogue in HCC occurrence in the absence of chronic viral hepatitis. This evidence concerns the gene INS and hepatocellular carcinoma.